Generic Drugs Are Tariff-Free Right Now. In Two Years, the Tariff Jumps to 100% — Then 200%

President Trump announced that generic drug imports into the US will carry a 0% tariff for a two-year period starting August 1, 2026. After that window closes, the tariff rises to 100% for one year, then rises again to 200% from 2029 onward — a three-stage schedule that starts at nothing and ends at triple the value of the drug.

The structure is deliberate rather than incidental. A tariff that started high immediately would raise generic drug costs right away, since manufacturing capacity can't be built overnight; a tariff that never escalated would give companies no reason to change anything. Trump framed the delay explicitly as a reshoring window: companies get a fixed period with no tariff at all to build manufacturing capacity inside the US, and the penalty only lands on whichever companies haven't done so by the time the 0% period ends. In that sense the policy is less a tax on imports today than a multi-year deadline attached to a very large financial consequence for missing it.

The policy is also narrowly scoped. It applies only to generic drugs — the version of a medicine sold after a patent expires, typically at a much lower price than the original branded product. Tariffs on patented, branded, and other innovative medicines are unaffected and continue to be governed separately from this announcement, so the immediate cost pressure this creates is concentrated in the generic-drug supply chain specifically, not pharmaceuticals broadly.